Selective NR2B antagonists

US8722670B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Dalton King · Hamden, US
• Richard E. Olson · Wilmington, US
• John E. Macor · Guilford, US
• Imadul Islam · Hercules, US
• Srinivasan Thangathirupathy · Hosur, IN
• Jayakumar Sankara Warrier · Bengaluru, IN

Key dates

• Filing date: Sep 26, 2012
• Grant date: May 13, 2014
• Expiry date: Sep 26, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.